To assess the therapeutic relevance of these hub genes, we queried the Genomics of Drug Sensitivity in Cancer (GDSC) database and found that their expression was associated with sensitivity to compounds targeting IRAK1, mTOR, and ATR, highlighting possible druggable vulnerabilities linked to CAF activity (Figure 4D). This evidence concerns the gene MTOR and cancer.